Clinical Trials
41 trialsNCT03092856 2026-06-03
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
University of Southern California
Phase 2 Active not recruiting
NCT03595124 2026-05-29
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05805501 2026-05-12
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT05327686 2026-05-04
SAMURAI
NRG Oncology
Phase 2 Recruiting
NCT05969496 2026-04-13
NEOPAX
University of Colorado, Denver
Phase 2 Recruiting
NCT07123090 2026-03-25
SPARCC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT07469683 2026-03-13
An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Yonsei University
Phase 2 Recruiting
NCT06860386 2026-03-06
Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Suspended
NCT07277972 2025-12-11
Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT04370509 2025-11-19
Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery
University of California, San Francisco
Phase 2 Terminated
NCT06962787 2025-11-17
A Study of BL-B01D1+TKIĀ±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT03438708 2025-10-02
PADRES
University of California, San Diego
Phase 2 Active not recruiting
NCT07172386 2025-09-16
Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC
Tianjin Medical University Second Hospital
Phase 2 Recruiting
NCT07159191 2025-09-08
Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
Peking Union Medical College Hospital
Phase 2 Not yet recruiting
NCT05256472 2025-03-06
A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma
Akeso
Phase 2 Active not recruiting
NCT06211114 2024-11-26
Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma
Peking University Cancer Hospital & Institute
Phase 2 Recruiting
NCT01693822 2024-11-21
A-PREDICT
Institute of Cancer Research, United Kingdom
Phase 2 Completed
NCT02639182 2024-11-18
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Astellas Pharma Inc
Phase 2 Completed
NCT06690697 2024-11-15
Combination of Toripalimab and JS004 Therapy for ccRCC
Fudan University
Phase 2 Recruiting
NCT01263769 2024-09-19
Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03472560 2024-04-09
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
Pfizer
Phase 2 Terminated
NCT02579811 2023-06-29
Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT05817903 2023-05-08
AxIn
Consorzio Oncotech
Phase 2 Recruiting
NCT01385059 2023-03-07
Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer
City of Hope Medical Center
Phase 2 Completed
NCT02489695 2022-09-06
AXIPAP
Centre Leon Berard
Phase 2 Completed
NCT05263609 2022-08-02
Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib
University of Oklahoma
Phase 2 Withdrawn
NCT01649180 2021-08-12
PrE0801
PrECOG, LLC.
Phase 2 Terminated
NCT04995016 2021-08-06
PANDORA
Tianjin Medical University Second Hospital
Phase 2 Unknown
NCT04958473 2021-07-12
SAARCC
Tianjin Medical University Second Hospital
Phase 2 Unknown
NCT03494816 2021-06-30
NAXIVA
Scottish Clinical Trials Research Unit
Phase 2 Completed
NCT01798446 2020-12-08
A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus
Seoul National University Hospital
Phase 2 Completed
NCT02187302 2020-05-28
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Lumos Pharma
Phase 2 Completed
NCT04385654 2020-05-13
Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma
West China Hospital
Phase 2 Unknown
NCT02700568 2019-10-22
FavorAx
Kidney Cancer Research Bureau
Phase 2 Completed
NCT03592199 2019-09-04
SuAx
Instituto do Cancer do Estado de SĆ£o Paulo
Phase 2 Unknown
NCT00569946 2019-06-05
Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)
Pfizer
Phase 2 Completed
NCT01441414 2019-01-08
PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Pfizer
Phase 2 Terminated
NCT02560012 2018-10-12
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT03341845 2018-05-21
Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC
The Netherlands Cancer Institute
Phase 2 Unknown
NCT00835978 2017-05-30
Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer
Pfizer
Phase 2 Completed
NCT00282048 2012-07-31
Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer
Pfizer
Phase 2 Completed